Ftse Mib
33.951,68
0,96%
DAX
18.158,52
0,92%
S&P 500
5.157,95
0,59%
NASDAQ
16.260,32
0,64%
Bitcoin
63.099,97
-1,40%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Immix Biopharma Inc (IMMX) Immix Biopharma Inc (IMMX) Notizie

Immix Biopharma Inc

IMMX
2,4636
0,1136 (4,83%)
Ultimo aggiornamento: 16:55:57
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
07/2/202423:15EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
06/2/202415:09EDGAR2Form 8-K - Current report
05/2/202422:38EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
05/2/202422:37EDGAR2Form 8-K - Current report
13/12/202300:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/11/202316:48IHNWImmix Biopharma Announces FDA Approval of IND Application..
10/11/202301:57EDGAR2Form 4/A - Statement of changes in beneficial ownership of..
25/9/202322:15EDGAR2Form S-3 - Registration statement under Securities Act of..
19/9/202301:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/9/202300:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/9/202322:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/8/202322:15EDGAR2Form SC 13D - General statement of acquisition of beneficial..
23/8/202322:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/8/202322:05EDGAR2Form 8-K - Current report
14/8/202322:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/8/202322:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/8/202322:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/8/202322:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/8/202322:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
25/7/202314:42GLOBEImmix Biopharma Subsidiary Nexcella Announces NXC-201..
17/7/202315:37GLOBEImmix Biopharma Reports 2nd Positive Interim Clinical Trial..
14/7/202323:28EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
14/7/202323:26EDGAR2Form 8-K - Current report
10/7/202315:47GLOBEImmix Biopharma Subsidiary Nexcella Completes Initial..
26/6/202315:49GLOBEImmix Biopharma Subsidiary Nexcella Completes Pre-IND..
22/6/202315:53GLOBEImmix Biopharma Subsidiary Nexcella Appoints Edward J...
20/6/202315:45GLOBEImmix Biopharma Subsidiary Nexcella Appoints Jeffrey H...
16/6/202315:43GLOBEImmix Biopharma Subsidiary Nexcella Appoints Mary Sue..
14/6/202313:30GLOBEImmix Biopharma Completes $5 Million At-The-Market Equity..
12/6/202315:49GLOBEImmix Biopharma Subsidiary Nexcella Appoints Henry..
26/5/202315:53GLOBEImmix Biopharma Subsidiary Nexcella Announces Commencement..
21/5/202322:05GLOBENexcella Announces Positive NXC-201 Clinical Results at..
21/5/202322:00GLOBEImmix Biopharma Announces Positive NXC-201 Clinical Results..
Apertura: 2,35 Min: 2,35 Max: 2,50
Chiusura: 2,35

La tua Cronologia

NASDAQ
IMMX
Immix Biopharma
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network